Last reviewed · How we verify
NCT04932031: SENSE
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
trial in Breast Cancer in 123 participants. Terminated before completion.
1 November 2023
Quick facts
| Lead sponsor | Sapere Bio |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 123 |
| Start date | 25 May 2022 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 November 2023 |
| Sites | 2 locations across United States |
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
- Aging — all drugs for Aging →
Sponsor
Sapere Bio
Who can join
18 and older, female only, with Breast Cancer or Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and the University of Alabama at Birmingham (UAB) Hospital). The primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing CIPN during chemotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer.
Mitin N, Nyrop KA, Strum SL, Knecht A, et al · · 2022 · cited 14× · PMID 36075910 · DOI 10.1038/s41523-022-00473-3
Verify or expand the search:
- PubMed search for NCT04932031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Sapere Bio trials
Trials by the same sponsor.
- NCT03635606 — GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04932031 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sapere Bio
- Last refreshed: 3 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing